Vnitr Lek 2026, 72(3):E5-E7 | DOI: 10.36290/vnl.2026.042

Immunosuppression with tacrolimus in kidney transplant recipients aged 65+

Silvie Rajnochová Bloudíčková1, Roman Šafránek2, Zdeněk Lys3, Karel Krejčí4, Milan Kuman5, Vladimír Hanzal1, Ondřej Viklický1
1 Klinika nefrologie, TC IKEM, Praha
2 Nefrologická klinika, FN Hradec Králové
3 Interní a kardiologická klinika, FN Ostrava
4 III. interní klinika, FN Olomouc
5 CKTCH Brno

Although the number of kidney transplant recipients aged 65+ is increasing, clear recommendations regarding immunosuppressive regimens have not yet been clearly defined. Immunosenescence increases the risk of post-transplant complications and adverse drug effects, contributing to a decline in quality of life, non-adherence, increased morbidity and mortality. The optimal strategy to minimize these complications is to take age and sensitization into account when accepting and allocating donors in order to limit the use of depletion induction therapy and utilize maintenance immunosuppression with lower toxicity.

Keywords: transplantation, immunosuppression, tacrolimus, immunosenescence, elderly, recommendation, toxicity.

Accepted: April 24, 2026; Published: May 18, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rajnochová Bloudíčková S, Šafránek R, Lys Z, Krejčí K, Kuman M, Hanzal V, Viklický O. Immunosuppression with tacrolimus in kidney transplant recipients aged 65+. Vnitr Lek. 2026;72(3):E5-7. doi: 10.36290/vnl.2026.042.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Attree C, et al. Ageing with grace and graft. Lancet Healthy Longev. 2024;5(7):e450-e451. Go to original source...
    2. Hart A, et al. OPTN/SRTR 2018 Annual Data Report: Kidney. Am J Transplant. 2020;20 Suppl s1:20-130. Go to original source...
    3. Lentine KL, et al. Immunosuppression Regimen Use and Outcomes in Older and Younger Adult Kidney Transplant Recipients: A National Registry Analysis. Transplantation. 2021;105(8):1840-1849. Go to original source...
    4. Tremblay S, et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. Am J Transplant. 2017;17(2):432-442. Go to original source...
    5. Rostaing L, et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. Am J Kidney Dis. 2016;67(4):648-659. Go to original source...
    6. Budde K, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant. 2014;14(12):2796-2806. Go to original source...
    7. Kamar N, et al. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Adv Ther. 2019;36(2):462-477. Go to original source...
    8. Griva K, Neo HLM, Vathsala A. Unintentional and intentional non-adherence to immunosuppressive medications in renal transplant recipients. Int J Clin Pharm. 2018;40(5):1234-1241. Go to original source...
    9. Cossart AR, et al. Investigating barriers to immunosuppressant medication adherence in renal transplant patients. Nephrology (Carlton). 2019;24(1):102-110. Go to original source...
    10. Huppertz A, et al. Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers. Clin Pharmacol Ther. 2019;106(6):1290-1298. Go to original source...
    11. von Einsiedel J, et al. Conversion from Standard-Release Tacrolimus to MeltDose((R)) Tacrolimus (LCPT) Improves Renal Function after Liver Transplantation. J Clin Med. 2020;9(6):???. Go to original source...
    12. Tholking G, et al. A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced Nephrotoxicity. J Clin Med. 2019;8(10):???. Go to original source...
    13. Jacobson PA, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326-3336. Go to original source...
    14. King CP, et al. The association between tacrolimus exposure and tremor, headache and insomnia in adult kidney transplant recipients: A systematic review. Transplant Rev (Orlando). 2024;38(1):100815. Go to original source...
    15. Langone A, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3 b study. Clin Transplant. 2015;29(9):796-805. Go to original source...
    16. Giral M, et al. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study. Transpl Int. 2024;37:11571. Go to original source...
    17. Krenzien F, et al. A Rationale for Age-Adapted Immunosuppression in Organ Transplantation. Transplantation. 2015;99(11):2258-2268. Go to original source...
    18. Nelson J, et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and International Society for Heart and Lung Transplantation: An executive summary. Pharmacotherapy. 2022;42(8):594-598. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.